Full Press Release Details
Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
of Experienced Dermatology CMO to Drive Clinical Advancement of MRX-6 --
YORK and LONDON, October 24, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage
biopharmaceutical company, announces the appointment of Pablo Jimenez, M.D., to the position of Chief Medical Officer. This appointment
reflects Celsus' continued growth as the company advances the development of its lead clinical asset, MRX-6, a non-steroidal
anti-inflammatory cream for the treatment of eczema and other skin inflammatory disorders.
are excited to have Dr. Jimenez join the Celsus team," said Gur Roshwalb, Chief Executive Officer of Celsus Therapeutics.
"Pablo brings a track record of success in developing dermatology compounds. His wealth of clinical and regulatory experience
will be invaluable as we advance our clinical pipeline."
Jimenez commented, "There is a significant need for safe and effective non-steroidal anti-inflammatory topical therapies
like MRX-6 for patients with eczema. I am excited to join Celsus at such a pivotal time in the company's evolution as it prepares
to advance MRX-6 into further clinical trials."
Jimenez has served more than two decades as a successful senior pharmaceutical executive in clinical development and medical affairs
within the dermatology, wound healing, respiratory, and oncology therapeutic areas. During his tenure at Novartis Pharmaceuticals,
Dr. Jimenez held positions of increasing responsibility including: Global Clinical Program Leader of Apligraf , Global Project
Section Leader of Elidel , Global Brand Medical Director of Xolair , Global Head of Medical Services and Global Head of
Medical Education & Communications. His career has spanned all levels of Development and Medical Affairs, including global
roles in the biopharmaceutical industry at Sotio, Human Genome Sciences, Neronyx and OsteoArthritis Sciences.
Jimenez has extensive clinical development expertise and knowledge about drug development in immunology and dermatology,"
said Professor Paul Carle, Chairman of the Department of Dermatology at Paul Sabatier University, Toulouse, France. "I have
had the pleasure of working with Pablo in the past and he brings a special expertise in bringing drugs from the bench to the bedside."
Jimenez received his M.D. from Central University School of Medicine in Ecuador and Master's Certificate in Project Management
from the George Washington University School of Business and Public Management. He did his Post-Doctoral research work at Brown
University, Division of Biology and Medicine.